ADCYAP1 and diabetic retinopathy: Accordingly, the beneficial effects of PACAP38 were studied not only in the aspects of retinal degenerative models (i.e. ischemia, diabetic retinopathy, glutamate, -and UVB-induced cell death) [7] but in the natural processes of retinal development and aging [6, 8].